---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-083568"
form_type: "8-K"
ticker: "VCNX"
cik: "0001205922"
company_name: "VACCINEX, INC."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:22:33.063625+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vaccinex raises ~$4.5M via multiple equity financings; issues Series A Preferred and warrants

## Summary
- Gross proceeds: ~$1.5M from RDO + PIPE (193K shares and warrants at $7.77/unit).
- Additional Private Placement: ~$1.25M from 159,683 shares and warrants at $7.77/unit; insiders participated.
- ADDF Transaction: $1.75M from Series A Preferred (5% cumulative dividend, convertible) and warrants for 229,057 shares.
- Warrants exercisable at $7.64/share, 5-year term; callable after positive SIGNAL-AD Alzheimer's data release.
- Lock-up on insiders through May 12, 2024; company restricted from most equity issuances until June 26, 2024.

## SEC filing metadata
- accession: 0001193125-24-083568
- form_type: 8-K
- ticker: VCNX
- cik: 0001205922
- company_name: VACCINEX, INC.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1205922/000119312524083568/0001193125-24-083568-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1205922/000119312524083568/d801492d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-083568
- JSON: https://secwatch.observer/filing/0001193125-24-083568.json
- Plain text: https://secwatch.observer/filing/0001193125-24-083568.txt

## Key facts
- Governance Changes
  VACCINEX, INC.: Filed Certificate of Designation of Series A Preferred Stock to create and establish rights, preferences and terms of the series (effective 2024-03-29).
  - Change: charter amendment
  - Effective: 2024-03-29
  source text: On March 29, 2024, the Company filed the Certificate of Designation of Series A Preferred Stock (the “Certificate”) with the Delaware Secretary of State, creating the Series A Preferred Stock and establishing the rights, preferences and other terms of the Series A Preferred Stock, and issued the Series A Preferred Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1205922/000119312524083568/0001193125-24-083568-index.htm
- Material Agreements
  VACCINEX, INC. entered into RDO Purchase Agreement with purchasers named therein valued at aggregate gross proceeds of approximately $1.5 million (effective 2024-03-27).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: purchasers named therein
  - Value: aggregate gross proceeds of approximately $1.5 million
  - Effective: 2024-03-27
  source text: On March 27, 2024, Vaccinex, Inc. (the “Company”) entered into a securities purchase agreement (the “RDO Purchase Agreement”) pursuant to which it agreed to issue and sell to the purchasers named therein (i) an aggregate of 193,000 shares (the “RDO Shares”) of the Company’s common stock (“Common Stock”) in a public offering and (ii) warrants (the “PIPE Warrants”) to purchase up to 193,000 shares of Common Stock in a concurrent private placement (collectively, the “AGP Transactions”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1205922/000119312524083568/0001193125-24-083568-index.htm
- Material Agreements
  VACCINEX, INC. entered into Advisory Agreement with A.G.P./Alliance Global Partners valued at cash fee equal to $140,000 and reimbursement of $75,000 (effective 2024-03-27).
  - Action: entry
  - Counterparty: A.G.P./Alliance Global Partners
  - Value: cash fee equal to $140,000 and reimbursement of $75,000
  - Effective: 2024-03-27
  source text: In connection with the AGP Transactions, on March 27, 2024, the Company entered into a financial advisory agreement (the “Advisory Agreement”) with A.G.P./Alliance Global Partners (the “Financial Advisor”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1205922/000119312524083568/0001193125-24-083568-index.htm
- Material Agreements
  VACCINEX, INC. entered into Private Placement Purchase Agreement with Private Placement Investors valued at aggregate gross proceeds of approximately $1.25 million (effective 2024-03-27).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Private Placement Investors
  - Value: aggregate gross proceeds of approximately $1.25 million
  - Effective: 2024-03-27
  source text: On March 27, 2024, the Company entered into a securities purchase agreement (the “Private Placement Purchase Agreement”) pursuant to which the Company agreed to issue and sell to the purchasers named therein (the “Private Placement Investors”) an aggregate of 159,683 shares (“Private Placement Shares”) of Common Stock together with warrants (“Private Placement Warrants”) to purchase up to 159,683 shares of Common Stock at a combined price of $7.77 per Private Placement Share and accompanying Private Placement Warrant (together, the “Private Placement Securities”) (the “Additional Private Placement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1205922/000119312524083568/0001193125-24-083568-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.